




Article

# Taurolidine Acts on Bacterial Virulence Factors and Does Not Induce Resistance in Periodontitis-Associated Bacteria—An In-Vitro Study

Sabrina Radakovic <sup>1</sup>, Nicola Andreoli <sup>1,†</sup>, Simon Schmid <sup>1,†</sup>, Sandor Nietzsche <sup>2</sup>,  
Jürg Zumbrunn <sup>3</sup>, Anton Sculean <sup>1</sup> and Sigrun Eick <sup>1,\*</sup> 

<sup>1</sup> Department of Periodontology, School of Dental Medicine, University of Bern, CH-3010 Bern, Switzerland; sabrina.radakovic@medi.ch (S.R.); nicola.andreoli@students.unibe.ch (N.A.); simon.schmid@students.unibe.ch (S.S.); anton.sculean@zmk.unibe.ch (A.S.)

<sup>2</sup> Center for Electron Microscopy, Jena University Hospital, D-07743 Jena, Germany; sandor.nietzsche@med.uni-jena.de

<sup>3</sup> Department of Clinical Affairs R& D, Geistlich Pharma Ag, CH-6110 Wolhusen, Switzerland; Juerg.Zumbrunn@geistlich.ch

\* Correspondence: sigrun.eick@zmk.unibe.ch

† Both contributed equally and share the second position.

Received: 10 February 2020; Accepted: 5 April 2020; Published: 7 April 2020



**Abstract:** The aims of the present study were: (a) to determine the mechanism of action of taurolidine against bacterial species associated with periodontal disease, and (b) to evaluate the potential development of resistance against taurolidine as compared with minocycline. After visualizing the mode of action of taurolidine by transmission electron micrographs, the interaction with most important virulence factors (lipopolysaccharide (LPS), *Porphyromonas gingivalis* gingipains, *Aggregatibacter actinomycetemcomitans* leukotoxin), was analyzed. Then, 14 clinical isolates from subgingival biofilm samples were transferred on agar plates containing subinhibitory concentrations of taurolidine or minocycline up to 50 passages. Before and after each 10 passages, minimal inhibitory concentrations (MICs) were determined. Increasing MICs were screened for efflux mechanism. Taurolidine inhibited in a concentration-dependent manner the activities of LPS and of the arginine-specific gingipains; however, an effect on *A. actinomycetemcomitans* leukotoxin was not detected. One *P. gingivalis* strain developed a resistance against taurolidine, which was probably linked with efflux mechanisms. An increase of MIC values of minocycline occurred in five of the 14 included strains after exposure to subinhibitory concentrations of the antibiotic. The present results indicate that: (a) taurolidine interacts with LPS and gingipains, and (b) development of resistance seems to be a rare event when using taurolidine.

**Keywords:** taurolidine; mechanisms of action; development of resistance; minocycline; periodontal pathogens

## 1. Introduction

According to the latest reported data about 42% of the non-institutionalized U.S. population has been diagnosed of periodontitis [1]. Periodontitis is a chronic inflammatory disease, which destructs the tooth's supporting tissues. In the pathogenesis of periodontitis, the host inflammatory response to subgingival bacteria leading to a pathogenic microbiota plays a central role [2]. Among the pathogenic microbiota, *Porphyromonas gingivalis* has been postulated to act as so called "key stone pathogen" [3] with its major virulence factors are cysteine proteases called gingipains [4]. Other bacteria involved in pathogenesis of periodontitis are *Tannerella forsythia* [5] and *Aggregatibacter actinomycetemcomitans*,

which synthesizes a leukotoxin [6]. *A. actinomycetemcomitans* strains differ in their ability to produce leukotoxin; e.g., highly leukotoxin-producing strains (JP2-clone) have a deletion in the promoter region [7].

Antimicrobials are frequently used for the treatment of periodontitis. The adjunctive use of chlorhexidine digluconate may additionally improve the clinical outcomes obtained with conventional mechanical debridement [8], while the use of adjunctive systemic antibiotics appears to be beneficial in the treatment of severe cases of periodontitis [9]. However, the long-term clinical benefit following the use of antibiotics is still unclear [10]. The topical use of minocycline microspheres (a tetracycline derivative) in conjunction with nonsurgical periodontal therapy has been shown to result in additional clinical improvements compared with nonsurgical periodontal therapy alone [11].

One potential alternative antimicrobial agent is taurolidine. Taurolidine is a derivative of the amino acid taurine, as an antimicrobial, it has been proven to be safe and effective for prevention of central venous catheter infection [12]. In vitro-studies indicate an antimicrobial activity against oral microorganisms also when those are organized in a biofilm [13,14]. Its potential application in dentistry has been discussed for several years. It has been shown that rinsing with 2% of taurolidine solution depressed growth of dental biofilm by about 50% [15]. In previous “in vitro” experiments we have evaluated some potential antimicrobial effects of taurolidine. We have shown that the minimal inhibitory concentrations (MIC)s of taurolidine were all below 1 mg/mL taurolidine with the exception of *Candida albicans* [13]. One percent of taurolidine inhibited clearly the formation of 12-species biofilms; however, the effect on an established biofilm was as limited as that of minocycline [16]. In an ex-vivo model using subgingival biofilm samples from periodontitis patients, the decrease of bacterial counts in biofilms was 0.87 log<sub>10</sub> cfu, corresponding to 86.5% following the application of 3% taurolidine gel after 60 min [17].

The development of resistance against antimicrobials is meanwhile a global problem, with more than half a million deaths annually being attributed to infections caused by antibiotic-resistant micro-organisms [18]. This is dependent on the used antibiotic; i.e., the relationship is strong when quinolones are used and rather weak when beta-lactams were applied [19]. In addition, a considerable number of studies have reported the development of resistance to commonly used antiseptics, and partly, cross-resistance with antibiotics was also found [20]. The increasing prevalence and spread of antimicrobial resistant bacteria are the natural consequence of genetic bacterial evolution. The more frequently an antimicrobial agent is used, the higher is the probability of resistance formation [21].


Antimicrobial agents' resistance in bacteria can be of different origin, with a distinction between intrinsic and acquired resistance mechanisms. Intrinsic resistance mechanism is a natural property of microorganisms. Acquired resistance mechanism is based on a genetic modification of the bacterium [22] and it can occur as the result of a mutation or the ingestion of foreign resistance genes. Besides the genetic potential of the microorganism, a present selection pressure of an antimicrobial is of importance, e.g., mutations can be induced by acclimating bacteria to increasing concentrations of antimicrobial agents [22]. Gene transfer, such as the acquisition of extra-chromosomal gene elements by transposons or plasmids, can occur within a few hours [23]. Bacterial antimicrobial resistance mechanisms are based on target alteration, impermeability, enzymatic modification or destruction and efflux [24], in case of resistance to biocides (e.g., chlorhexidine) membrane modification or efflux is involved [25].

The aims of this follow-up study were: a) to determine in more detail the mode of action of taurolidine against bacterial species being associated with periodontal disease, and b) to verify a potential development of resistance against taurolidine as compared to that against minocycline. Our data of the present study suggest an inhibition of lipopolysaccharide (LPS) and of *P. gingivalis* gingipains by taurolidine. In comparison with minocycline, the development of resistance to taurolidine was rare in the in-vitro experiments.

## 2. Results

### 2.1. Visualization of Taurolidine Action


Differences of transmission electron micrographs (TEM) of *P. gingivalis* ATCC 33,277 and *T. forsythia* Be13237 without and with 2 h exposure to 1% taurolidine were small (Figure 1). After exposure to taurolidine, a decomposition of the cytoplasm leading to unstained areas within the *P. gingivalis* cells was visible (Figure 1).



**Figure 1.** Transmission electron micrographs (TEM) images of *Porphyromonas gingivalis* ATCC 33277 and *Tannerella forsythia* Be13237 after treatment with 1% taurolidine for 2 h, in comparison to its control. *P. gingivalis* shows a decomposition of the cytoplasm leading to unstained areas (arrowheads). For *T. forsythia*, no difference could be found. Scale bars: 200 nm.


### 2.2. Interaction with Most Important Virulence Factors

Taurolidine inhibited concentration-dependent the endotoxic activity of *Escherichia coli* LPS, *P. gingivalis* LPS, and of *P. gingivalis* ATCC 33,277 and *A. actinomycetemcomitans* Y4. (As *P. gingivalis* LPS has less endotoxin activity [26], a higher concentration was used in comparison with *E. coli* LPS.) Statistically significant differences were always found when comparing 1% taurolidine with control. In contrast, 16 µg/mL of minocycline did not have any effect (Figure 2).



**Figure 2.** Endotoxin activity (endotoxin units (EU), mean  $\pm$  SD) measured by Limulus amoebocyte lysate assay of *Escherichia coli* (E.c.) LPS, *Porphyromonas gingivalis* (P.g.) LPS as well as *P. gingivalis* ATCC 33277 and *Aggregatibacter actinomycetemcomitans* Y4, without and with 2 h pre-exposure to 0.01%, 0.25%, 1% taurolidine (TAU) and 16  $\mu$ g/mL minocycline (MINO). \*  $p < 0.05$ , \*\*  $p < 0.01$  vs. respective control.


Next, the effect of taurolidine on viability of monocytic MONO-MAC-6 cells measured by MTT assay was determined. The results underline the toxicity of purified *A. actinomycetemcomitans* leukotoxin; the viability of the cells was 17%, after 1 h and 8.4% after 20 h related to the non-treated cells. Between the two used bacterial strains, the Be12206 strain belonging to the JP2 clone (well-known for being highly leukotoxic) decreased the viability of the cells to 12.3% after 20 h of incubation. An inhibitory effect of the added antimicrobials (both taurolidine in three concentrations and 16  $\mu$ g/mL minocycline) on toxicity of leukotoxin to MONO-MAC-6-cells was not seen (Figure 3). In contrast, in this assay an exposure to taurolidine clearly decreased the MTT activity, the effect was visible for 0.25% and 1% of taurolidine already after 1 h and for all three used concentrations after 20 h (each  $p < 0.01$ ).



**Figure 3.** MTT activity (mean  $\pm$  SD) of monocytic MONO-MAC-6 cells after infection with different *Aggregatibacter actinomycetemcomitans* strains (Be12206, Be14207), after addition of leukotoxin (Ltx, 4  $\mu$ g/mL) and exposure to 0.01%, 0.25%, and 1% taurolidine (TAU) as well as to 16  $\mu$ g/mL minocycline (MINO). \*  $p < 0.05$ , \*\*  $p < 0.01$  vs. respective control.

Taurolidine blocked the activity of the purified *P. gingivalis* arginine specific cysteine protease (RgpB). Using bacterial strains of *P. gingivalis*, the results were different. Applying 1% taurolidine to *P. gingivalis* ATCC 33277 and J374-1, the measured arginine-specific amidolytic activity clearly

decreased, whereas 0.01% did not exert any effect on the enzyme activity. In contrast, when using the HG66 strain, nearly no arginine-specific amidolytic activity was found already after bacterial culture was exposed to 0.01% taurolidine. Results for minocycline were similar for the purified gingipain and the HG66 strain, but there was no inhibition of gingipain activity when using the ATCC 33277 and the J374-1 strains (Figure 4).



**Figure 4.** Arginine specific amidolytic activity (Arg act) measured by  $\Delta$  abs 405 nm after addition of taurolidine (TAU; a,c,e,g) and minocycline (MINO; b,d,f,h) in different concentrations to 10 nM RgpB (a,b), *Porphyromonas gingivalis* ATCC 33277 (c,d), *P. gingivalis* J374-1 (e,f) and *P. gingivalis* HG66 (g,h).

### 2.3. Potential Development of Resistance

Analyzing a potential development of resistance, an increase of MIC of taurolidine was found only against one *P. gingivalis* strains after 20 passages. But it is of interest to note that four strains, among them the two included *T. forsythia* strains, became more susceptible to the antimicrobial after certain passages (both *T. forsythia* after 10 passages, one *P. gingivalis* after 20 passages and *Streptococcus constellatus* after 50 passages; Table S1). Resistance development against minocycline was found in five of the 14 included strains after exposure to subinhibitory minocycline (Table S2).

Next, strains exhibiting an altered susceptibility after certain passages were characterized further. The increase of the MIC of taurolidine against one strain (*P. gingivalis* J374-1) might be linked to efflux mechanisms. It seems that this strain contains several efflux pumps. After removing antimicrobial pressure for three passages, MIC values were equal or close to baseline values (Table 1). Efflux mechanisms might play also a role in two *A. actinomycetemcomitans* strains showing an increase in resistance against minocycline. It is obviously not of importance in the other three strains with increased MIC values. Removing antimicrobial pressure for a few passages did not revert the increased MIC values of minocycline (Table 2).

**Table 1.** MIC of taurolidine (% w/v) of strains with changed MIC values after 50 passages on subinhibitory concentrations of taurolidine. Presented are MIC values before and after 50 passages, after addition of efflux inhibitors reserpine, NMP, CCCP, verapamil (only strain showing increase of MIC) as well as after additional three passages on agar plates free of antimicrobials.

Strain	Baseline	After 50 Pass.	With 20 µg/mL Reserpine	With 50 µg/mL NMP	With 10 µg/mL CCCP	With 100 µg/mL Verapamil	After 3 pass. w/o Taurolidine
<i>P. gingivalis</i> J374-1	0.025	0.1	0.013	0.013	0.006	0.006	0.025
<i>S. constellatus</i> BeTa7-1	0.1	0.025	n.d.	n.d.	n.d.	n.d.	0.05
<i>T. forsythia</i> Be13237	0.025	≤0.003	n.d.	n.d.	n.d.	n.d.	0.025
<i>T. forsythia</i> Be13216	0.025	≤0.003	n.d.	n.d.	n.d.	n.d.	0.013


pass. = passages; n.d. = not done.

**Table 2.** MIC of minocycline (µg/mL) of strains with changed MIC values after 50 passages on subinhibitory concentrations of minocycline. Presented are MIC values before and after 50 passages, after addition of efflux inhibitors reserpine, NMP, CCCP, verapamil, as well as after additional three passages on agar plates free of antimicrobials

Strain	Baseline	After 50 pass.	With 20 µg/mL reserpine	With 50 µg/mL NMP	With 10 µg/mL CCCP	With 100 µg/mL verapamil	After 3 pass. w/o MINO
<i>Streptococcus oralis</i> JM933	1	4	4	4	4	4	4
<i>A. actinom.</i> OMZ 444	1	32	8	≤0.5	≤0.5	8	32
<i>A. actinom.</i> Be14207	8	32	8	16	32	4	32
<i>Fusobacterium nucleatum</i> BeTa9-1	1	4	4	4	4	4	4
<i>T. forsythia</i> Be13216	0.5	2	2	2	2	2	2

pass. = passages; A. actinom. = *A. actinomycetemcomitans*.

In the TEM images of *P. gingivalis* J374-1, highly dense particles are visible after exposure to subinhibitory taurolidine. Within the bacterial cells, dense structures are located in the cells. TE micrographs of *T. forsythia* Be13237 show dense structures surrounded by a halo attached to the outer membrane (Figure 5).



**Figure 5.** TEM images of *Porphyromonas gingivalis* J374-1ATCC 33,277 and *Tannerella forsythia* Be13237 after 50 passages on agar plates containing subinhibitory concentrations of taurolidine in comparison to its control. *P. gingivalis* J374-1 (a strain becoming more resistant to taurolidine) shows dense particles within cytoplasm (arrowheads). For *T. forsythia* Be13237 (a strain becoming more susceptible) dense structures at the cell wall surrounded by a halo (arrow) were be found. Scale bars: 200 nm.

### 3. Discussion

In the present study, the mode of action of taurolidine against bacterial species associated with periodontitis and the potential development of resistance were analyzed.

The inhibition of endotoxin activity suggests a potential interaction of taurolidine with the bacterial cell wall. Taurolidine is active against gram-positive and gram-negative bacteria [27]. Taurolidine undergoes several hydrolysis reactions, first a cationic taurolidine is formed [28], which may attack the negatively charged bacterial cell wall. This is a mechanism known for other antimicrobials, e.g., charged chlorhexidine binds to the bacterial cell membranes [29]. For taurolidine, non-isolable carbinolamine is the major bactericidal compound, the antimicrobial activity originates from the methylene iminium ion production [30]. An endotoxin-inactivation has been discussed for many years as taurolidine inhibited concentration-dependent the expression of inflammatory cytokines induced by LPS in peripheral blood mononuclear cells [31]. In contrast, no clear reactivity of taurolidine and its derivatives with peptidoglycan was found [28].

In our study, taurolidine neutralized the endotoxic activity of LPS. This included the LPS derived from *E. coli* and *P. gingivalis* LPS, which showed less endotoxin activity. *P. gingivalis* synthesizes two types of LPS, the O-LPS with O-antigens, and an anionic A-LPS with nonphosphorylated penta-acylated and nonphosphorylated tetra-acylated species, the latter one is less active in stimulating cytokine production in MONO-MAC-6 cells than total *P. gingivalis* LPS [26].

LPS of *A. actinomycetemcomitans* is involved in the secretion of its leukotoxin, an LPS with altered O-antigen polysaccharide leads to an increase of membrane-bound leukotoxin [32]. However, in our study, we have failed to show an inhibition of leukotoxin activity by taurolidine. The MTT tetrazolium salt colorimetric assay described by Mosmann (1983) was used to measure viability of MONO-MAC-6 cells; it confirmed the toxicity of leukotoxin and of a highly-leukotoxic *A. actinomycetemcomitans* belonging to the JP2 clone. Viability of the MONO-MAC-6 cells decreased after being in contact with taurolidine. The observed toxicity is in contrast to a report using peripheral blood monocytes where no

toxicity was found up to 10% taurolidine [31]. The difference might be explained by the origin of cells. Although MONO-MAC-6 cells are very similar in their expression profile to mature monocytes they originate from a leukemia patient [33].

Except for the *A. actinomycetemcomitans* leukotoxin, we focused on a potential interaction with *P. gingivalis* gingipains. Gingipains are membrane-associated proteases functioning in proteolytic processing of nutrients, adhesion to host cells, evasion of immune response and more attributes [34,35]. The arginine specific amidolytic activity of the purified cysteine protease RgpB and of different strains was clearly inhibited until blocked by taurolidine. Total blocking was found when RgpB and bacterial culture of the HG66 strain were exposed to 1% taurolidine. Thus, it can be concluded that taurolidine inhibits directly gingipain activity. The HG66 strain is the only exception of all *P. gingivalis* strains where gingipains are not glycosylated and bound to outer membranes or outer membrane vesicles but released in a non-glycosylated soluble form into extracellular milieu [4].

In the present study, we compared the potential development of resistance of taurolidine versus minocycline on species being associated with periodontitis. Exposing microbial strains to subinhibitory concentrations of an antimicrobial for certain passages is a widely used method to evaluate the potential of an antimicrobial for development of resistance [36,37]. The results have shown an increase of MIC of taurolidine against only one *P. gingivalis* strain (374-1), whereas a resistance development against minocycline was found in five of the 14 included strains after exposure to subinhibitory concentrations of the respective antimicrobial.

The increase of resistance of taurolidine against one strain (*P. gingivalis* J374-1) might be linked to efflux mechanisms. The efflux seems to be a first line of defense against an antimicrobial by pumping out the antimicrobial and decreasing its level within the bacterial cell [38]. Efflux pumps can be switched on when even low concentrations of an antimicrobial are in the cell, leading to an adaptive resistance, and expression is downregulated when the antimicrobial agent is absent [38]. The process of active efflux is one of the important mechanisms of resistance against antibiotics but also against antiseptics [39]. A *Chryseobacterium indologenes* strain, which was isolated from oral biofilm up-regulated expression of an efflux-pump system in the presence of chlorhexidine digluconate [40]. Higher MIC values of chlorhexidine digluconate against *Pseudomonas aeruginosa* and *Staphylococcus aureus* strains were decreased by adding efflux pump inhibitors [41]. Efflux pumps belong to five families, regarding antimicrobial resistance the ABC pumps in gram-positive bacteria and the RND pumps in gram-negative bacteria are most important [42]. All used inhibitors on efflux pumps increased the sensitivity of the *P. gingivalis* J374-1 strain to taurolidine. Among the used inhibitors, 1-(1-naphthylmethyl)piperazine (NMP) and carbonyl cyanide 3-chlorophenylhydrazone (CCCP) are known to inhibit RND pumps, whereas reserpine and verapamil act on non-RND pumps [43,44]. This leads to the assumption that both RND and non RND-pumps were involved in the adaptive resistance. After three passages of *P. gingivalis* J374-1 on media free of antimicrobials, the MIC of taurolidine, the MICs, became lower than at baseline, which suggests a certain activity of the pumps already before antimicrobial's exposure.

Interestingly, a few strains became more susceptible to taurolidine when being exposed to subinhibitory concentrations of the antimicrobial. However, this phenomenon is difficult to explain. TEM images depicted areas of halos closed to cell bacterial cell wall leading to the assumption of an enrichment of the antimicrobial there. This might be supported by the fact that the higher susceptibility got lost after a few passages of the strain on agar plates without antimicrobials.

A resistance development against minocycline was found in five of the 14 included strains after exposure to subinhibitory minocycline. As doxycycline, minocycline belongs to the second generation of tetracyclines, an antibiotic class, which target is the small subunit of bacterial ribosome where t-RNA binds to the respective nucleic acids of mRNA [45]. Acquired resistance is linked with efflux pumps, but also bacterial proteins removing tetracyclines from its binding site, enzymes degrading tetracyclines or mutations within 16S rRNA preventing binding of tetracyclines to ribosomes exist [45]. Resistance to tetracyclines among oral strains is reported differently. Recently about 30% of *Streptococcus intermedius* and *S. constellatus* strains and 47% of the *A. actinomycetemcomitans* were reported



to be resistant against doxycycline [46,47]. In contrast, less than 10% of *A. actinomycetemcomitans* strains isolated from aggressive periodontitis patients in Great Britain showed a resistance against tetracyclines [48] and MIC<sub>90</sub> values were generally low for *P. gingivalis* and for *F. nucleatum* [49]. In two (both *A. actinomycetemcomitans* strains) out of the five strains with higher MIC values to minocycline, the efflux mechanism seem to play a role; in one strain this might be related mainly to RND pumps, in the other strain only to non-RND pumps. In the other three strains (one *T. forsythia*, one *F. nucleatum* and one oral streptococcus), other mechanisms, which have not been investigated in detail, may account for the increased MIC values. However, it is of interest to note that removing antimicrobial pressure for a few passages did not revert the increased MIC values. In a previous study, most oral bacteria survived transitory 2–8-fold MIC values of minocycline but finally, the MIC values were not different from those at baseline (at the highest one step) [50].

## 4. Materials and Methods

### 4.1. Antimicrobials

In all experiments, taurolidine 2% solution (Geistlich Pharma AG, Wolhusen, Switzerland) was used and diluted until to the necessary dilution. As positive control minocycline (Sigma-Aldrich, Buchs, Switzerland) and as negative control dH<sub>2</sub>O were used.

### 4.2. Microorganisms

Several oral bacterial strains (laboratory strains and clinical isolates; mainly *P. gingivalis* and *A. actinomycetemcomitans*) were included in the experiments (Table S3). The clinical isolates (4 *P. gingivalis*, 3 *A. actinomycetemcomitans*, 2 *T. forsythia*, 2 *Fusobacterium nucleatum*, 4 oral streptococci) were obtained from subgingival biofilm samples. Samples were only obtained from individuals who did not receive antibiotic treatment 2 months prior to the date of collecting. Culturing subgingival biofilm and isolation of respective bacterial strains was approved by the Ethical Committee of the Canton Bern (KEK 096/15). Without removing of supragingival biofilm, sterile paper point (ISO 50) were inserted into the periodontal pocket for 30 s. Then, the pooled paper points were placed into 1 mL of reduced transport fluid. After culturing on tryptic-soy-agar-plates with 5% of sheep blood (Oxoid, Basingstoke, GB) under anaerobic conditions for 8 d, colonies typical for the respective species were isolated and subcultivated. Identity was confirmed by PCR using species-specific primers [51].

Bacterial strains were kept frozen at −80 °C. About one week before experiments, they were subcultured and passaged 2–3 times on tryptic-soy-agar plates with 5% of sheep blood.

### 4.3. Cells

Monocytic cells of human origin (MONO-MAC-6; DSMZ no. ACC 124) were maintained in RPMI 1640 medium containing 10% fetale bovine serum (FBS). For experiments, cells were used in M199 media without FBS (Invitrogen; Carlsbad, CA, USA).

### 4.4. TEM Images after Exposure to 1% Taurolidine

Two bacterial strains (*P. gingivalis* ATCC 33277, *T. forsythia* B13237) were included. They were suspended to a density of about McFarland 4 in nutrient broth (Wilkins–Chalgren broth (Oxoid) supplemented with 5 mg/L β-NAD and 10 mg/L NAM (both Sigma-Aldrich, Buchs, Switzerland)) without and with 1% of taurolidine. After an incubation for 2 h in an anaerobic atmosphere at 37 °C, these bacteria were prepared for transmission electron microscopy (TEM).

For TEM, bacteria suspensions were fixed with 0.5% formaldehyde and 2% glutaraldehyde in 0.1 M cacodylate buffer (pH 7.4) for 30 min. After washing 3-fold with 0.1 M cacodylate buffer 10 min each and post-fixating with 1% osmiumtetroxide for 1 h, dehydration in ascending ethanol series (30%, 50%, 70%, 80%, 90%, 100%, 10 min each) was performed. Moreover, after, the 50% stage post-staining with 2% uranylacetate in 50% ethanol for 2 h in the dark was conducted. Afterwards, the samples

were embedded in epoxy resin (Araldite) and sectioned using a Leica Ultracut E (Leica, Wetzlar, Germany). Ultrathin sections (60 nm thickness) were mounted on filmed Cu grids (Formvar/carbon film, Quantifoil Micro Tools GmbH, Jena, Germany), post-stained with lead citrate for 5 min, and studied in a transmission electron microscope (EM 900, Zeiss, Oberkochen, Germany) at 80 kV and magnifications of 3000× to 20,000×. All preparation steps were performed at room temperature.

#### 4.5. Interaction with Bacterial Virulence Factors

To determine a potential effect of taurolidine on lipopolysaccharide (LPS), 10 pg and 100 pg LPS originated from *Escherichia coli* (Sigma-Aldrich) and 10 ng LPS from *P. gingivalis* (InvivoGen, Toulouse, France) were used. Taurolidine in the final concentrations of 0.01% *w/v*, 0.25% *w/v* and 1% *w/v* and as control 16 µg/mL minocycline were added to the LPS for 2 h at 37 °C. Thereafter, endotoxin activity was measured by Limulus amoebocyte lysate assay (LAL) QCL-1000™ test (Lonza, Basel, Switzerland) according to the manufacturer's recommendation. Moreover, the two bacterial strains *P. gingivalis* ATCC 33277 and *A. actinomycetemcomitans* Y4 (about 10<sup>8</sup>/mL) were exposed to the same concentrations of antimicrobials for 2 h before measuring endotoxin activity.

The leukotoxin was purified as described by Kachlany et al. [52], by adding a final centrifugation using 10 kDa centrifugal filter to remove proteins of lower weights. Leukotoxin in a concentration of 4 µg/mL and two *A. actinomycetemcomitans* strains (10<sup>8</sup>/mL in M199 media) were exposed to three concentrations of taurolidine (0.01% *w/v*, 0.5% *w/v*, 1.5% *w/v*) and to 16 mg/mL minocycline for 2 h before monocytic cells (10<sup>6</sup>/mL in M199 media) were added in a ratio 1:1. *A. actinomycetemcomitans* leukotoxin is well known to affect viability of leukocytes, such as monocytes [6].) Viability of MONO-MAC-6 cells was determined after 1 h and 20 h of incubation at 37 °C with 5% of CO<sub>2</sub> by using ((3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) tetrazolium) MTT assay according to Mosmann [53], which quantifies the amount of MTT reduced by the cells to its formazan derivative.

Experiments on LPS and leukotoxin activity were made in independent triplicates. One-way ANOVA with post-hoc Bonferroni compared different antimicrobials with controls each. Further, *t*-test was used to find differences in viability of MONO-MAC-6 cells after exposing *A. actinomycetemcomitans* strains and leukotoxin with non-stimulate cells (only controls). A difference with a *p*-value of <0.05 was considered as being statistically significant each.

A direct inhibitory effect on gingipain activity was assessed by adding three concentrations of taurolidine (0.01% *w/v*, 0.25% *w/v*, 1% *w/v*) and of minocycline (0.5 µg/mL, 16 µg/mL, 128 µg/mL) for 2 h to 10 nM activated RgpB (being an arginine-specific gingipain; the RgpB was kindly provided by Jan Potempa, Jagiellonian University Krakow, Poland). Thereafter, *P. gingivalis* strains (10<sup>8</sup>/mL Wilkins–Chalgren broth) were exposed to the same concentrations of the antimicrobials for 2 h (anaerobic atmosphere, 37 °C) before measuring arginine specific amidolytic activity in the suspensions by adding the chromogenic *N*-α-benzoyl-DL-arginine-*p*-nitroanilide (BAPNA) substrate (Sigma-Aldrich), USA, with a final concentration of 2 mM in the assay buffer (0.2M Tris-HCl, 0,1M NaCl, 5 mM CaCl<sub>2</sub>, pH 7.6, supplemented with 10 nM cysteine hydrochloride solution in a ratio 1:1. The absorbance was read at 405 nm (37 °C) at 30 s intervals for 1 h by using a spectrophotometer (BioTek EL808, BioTek, Luzern, Switzerland).

#### 4.6. Potential Development of Resistance

Initially, all clinical isolates were included in this experiment. However, the *A. actinomycetemcomitans* Be12206 strain did not survive the passages. Therefore, only results from 14 strains were available. The method was adapted to the procedures made before [37,54]. For that, strains were transferred on Wilkins–Chalgren agar plates (Oxoid) containing 1/4–1/8 of the MICs of taurolidine or minocycline up to 50 passages of the respective strain (about one passage each five days). Before and after each 10 passages, MICs were determined again by agar dilution technique (Wilkins–Chalgren agar plates plus respective concentration of the antimicrobial). If there was an increase or decrease of MICs after passing, the concentration of the antimicrobial was adapted. Further strains with altered MICs

were passaged 3 times on media free of antimicrobials to see the stability of the altered MIC. Strains showing changed MIC before and after 50 passages with subinhibitory concentrations of taurolidine were prepared for TEM and SEM, as described above.

Strains with increased MICs were screened for potential efflux resistance mechanisms. The efflux inhibitors 50 µg/mL NMP, 10 µg/mL CCCP, 100 µg/mL verapamil, and 20 µg/mL reserpine (all inhibitors Sigma-Aldrich) were added to the nutrient media (Wilkins–Chalgren broth) together with antimicrobials. The MICs were determined after 18 h of incubation.

## 5. Conclusions

Taurolidine interacts with LPS of periodontopathogens and inhibits the activity of gingipains. Since the development of resistance against taurolidine occurs very rarely when compared with that induced by minocycline, further studies are warranted to evaluate its potential use in the treatment of periodontal and peri-implant infections.

**Supplementary Materials:** The following are available online at <http://www.mdpi.com/2079-6382/9/4/166/s1>, Table S1: Minimal inhibitory concentration (MIC) of taurolidine (% w/v) determined at baseline and after certain passages on agar plates containing subinhibitory concentrations of the compound; Table S2: Minimal inhibitory concentration (MIC) of minocycline (µg/mL) at baseline and after certain passages on agar plates containing subinhibitory concentrations of the compound; Table S3: Strains included in the experiments.

**Author Contributions:** Conceptualization, S.E. and J.Z.; methodology, S.E. and S.N.; investigation, S.R., S.S. and N.A.; data curation, S.E.; writing—original draft preparation, S.E., S.R., S.S. N.A. and S.N.; writing—review and editing, S.E., J.Z., and A.S.; visualization, S.N.; supervision, S.E.; funding acquisition, S.E. and A.S. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research was funded by Geistlich Pharma AG, Wolhusen, Switzerland.

**Acknowledgments:** The authors are grateful to Fabiola Costanzo, Anna Magdoń, and Ekaterina Volkova (Department of Periodontology, Laboratory of Oral Microbiology, University of Bern) for their excellent assistance in performing the in vitro assays. Franziska Suter (Institute for Infectious Diseases, University of Bern) is acknowledged for help in identification of bacterial species.

**Conflicts of Interest:** The funder had no role in data collection and analysis, decision to publish, Jürg Zumbrunn (employee of Geistlich Pharma AG) had limited role in study design, or preparation of the manuscript. All other authors declare no conflict of interest.

## References

1. Eke, P.I.; Thornton-Evans, G.O.; Wei, L.; Borgnakke, W.S.; Dye, B.A.; Genco, R.J. Periodontitis in US Adults: National Health and Nutrition Examination Survey 2009–2014. *J. Am. Dent. Assoc.* **2018**, *149*, 576–588. [\[CrossRef\]](#) [\[PubMed\]](#)
2. Mark Bartold, P.; Van Dyke, T.E. Host modulation: Controlling the inflammation to control the infection. *Periodontol 2000* **2017**, *75*, 317–329. [\[CrossRef\]](#) [\[PubMed\]](#)
3. Hajishengallis, G. Periodontitis: From microbial immune subversion to systemic inflammation. *Nat. Rev. Immunol.* **2015**, *15*, 30–44. [\[CrossRef\]](#) [\[PubMed\]](#)
4. Guo, Y.; Nguyen, K.A.; Potempa, J. Dichotomy of gingipains action as virulence factors: From cleaving substrates with the precision of a surgeon’s knife to a meat chopper-like brutal degradation of proteins. *Periodontol 2000* **2010**, *54*, 15–44. [\[CrossRef\]](#)
5. Sharma, A. Virulence mechanisms of *Tannerella forsythia*. *Periodontol 2000* **2010**, *54*, 106–116. [\[CrossRef\]](#)
6. Herbert, B.A.; Novince, C.M.; Kirkwood, K.L. *Aggregatibacter actinomycetemcomitans*, a potent immunoregulator of the periodontal host defense system and alveolar bone homeostasis. *Mol. Oral Microbiol.* **2016**, *31*, 207–227. [\[CrossRef\]](#)
7. Brogan, J.M.; Lally, E.T.; Poulsen, K.; Kilian, M.; Demuth, D.R. Regulation of *Actinobacillus actinomycetemcomitans* leukotoxin expression: Analysis of the promoter regions of leukotoxic and minimally leukotoxic strains. *Infect. Immun.* **1994**, *62*, 501–508. [\[CrossRef\]](#)
8. Da Costa, L.; Amaral, C.; Barbirato, D.D.S.; Leao, A.T.T.; Fogacci, M.F. Chlorhexidine mouthwash as an adjunct to mechanical therapy in chronic periodontitis: A meta-analysis. *J. Am. Dent. Assoc.* **2017**, *148*, 308–318. [\[CrossRef\]](#)

9. Zandbergen, D.; Slot, D.E.; Niederman, R.; Van der Weijden, F.A. The concomitant administration of systemic amoxicillin and metronidazole compared to scaling and root planing alone in treating periodontitis: =a systematic review=. *BMC Oral Health* **2016**, *16*, 27. [[CrossRef](#)]
10. Harks, I.; Koch, R.; Eickholz, P.; Hoffmann, T.; Kim, T.S.; Kocher, T.; Meyle, J.; Kaner, D.; Schlagenhauf, U.; Doering, S.; et al. Is progression of periodontitis relevantly influenced by systemic antibiotics? A clinical randomized trial. *J. Clin. Periodontol.* **2015**, *42*, 832–842. [[CrossRef](#)]
11. Salvi, G.E.; Mombelli, A.; Mayfield, L.; Rutar, A.; Suvan, J.; Garrett, S.; Lang, N.P. Local antimicrobial therapy after initial periodontal treatment. *J. Clin. Periodontol.* **2002**, *29*, 540–550. [[CrossRef](#)] [[PubMed](#)]
12. Wouters, Y.; Theilla, M.; Singer, P.; Tribler, S.; Jeppesen, P.B.; Pironi, L.; Vinter-Jensen, L.; Rasmussen, H.H.; Rahman, F.; Wanten, G.J.A. Randomised clinical trial: 2% taurolidine versus 0.9% saline locking in patients on home parenteral nutrition. *Aliment. Pharmacol. Ther.* **2018**, *48*, 410–422. [[CrossRef](#)] [[PubMed](#)]
13. Eick, S.; Radakovic, S.; Pfister, W.; Nietzsche, S.; Sculean, A. Efficacy of taurolidine against periodontopathic species—an in vitro study. *Clin. Oral Investig.* **2012**, *16*, 735–744. [[CrossRef](#)] [[PubMed](#)]
14. Reynolds, S.; Moran, J.; Addy, M.; Wade, W.G.; Newcombe, R. Taurolin as an oral rinse. I. Antimicrobial effects in vitro and in vivo. *Clin. Prev. Dent.* **1991**, *13*, 13–17. [[PubMed](#)]
15. Muhlemann, H.R.; Strub, J.R. Inhibition of plaque growth with taurolin, vantocil and amine fluoride. *Helv. Odontol. Acta* **1975**, *19*, 57–60. [[PubMed](#)]
16. Zollinger, L.; Schnyder, S.; Nietzsche, S.; Sculean, A.; Eick, S. In-vitro activity of taurolidine on single species and a multispecies population associated with periodontitis. *Anaerobe* **2015**, *32*, 18–23. [[CrossRef](#)]
17. Pirracchio, L.; Joos, A.; Luder, N.; Sculean, A.; Eick, S. Activity of taurolidine gels on ex vivo periodontal biofilm. *Clin. Oral Investig.* **2018**, *22*, 2031–2037. [[CrossRef](#)]
18. Allcock, S.; Young, E.H.; Holmes, M.; Gurdasani, D.; Dougan, G.; Sandhu, M.S.; Solomon, L.; Torok, M.E. Antimicrobial resistance in human populations: Challenges and opportunities. *Glob. Health Epidemiol. Genom.* **2017**, *2*, e4. [[CrossRef](#)]
19. Bell, B.G.; Schellevis, F.; Stobberingh, E.; Goossens, H.; Pringle, M. A systematic review and meta-analysis of the effects of antibiotic consumption on antibiotic resistance. *BMC Infect. Dis.* **2014**, *14*, 13. [[CrossRef](#)]
20. McDonnell, G.; Russell, A.D. Antiseptics and disinfectants: Activity, action, and resistance. *Clin. Microbiol. Rev.* **1999**, *12*, 147–179. [[CrossRef](#)]
21. White, D.G.; McDermott, P.F. Biocides, drug resistance and microbial evolution. *Curr. Opin. Microbiol.* **2001**, *4*, 313–317. [[CrossRef](#)]
22. Russell, A.D. Bacterial resistance to disinfectants: Present knowledge and future problems. *J. Hosp. Infect.* **1999**, *43*, S57–S68. [[CrossRef](#)]
23. Russell, A.D. Mechanisms of bacterial insusceptibility to biocides. *Am. J. Infect. Control.* **2001**, *29*, 259–261. [[CrossRef](#)]
24. Poole, K. Mechanisms of bacterial biocide and antibiotic resistance. *J. Appl. Microbiol.* **2002**, *92 Suppl*, 55S–64S. [[CrossRef](#)]
25. Cieplik, F.; Jakubovics, N.S.; Buchalla, W.; Maisch, T.; Hellwig, E.; Al-Ahmad, A. Resistance Toward Chlorhexidine in Oral Bacteria—Is There Cause for Concern? *Front. Microbiol.* **2019**, *10*, 587. [[CrossRef](#)] [[PubMed](#)]
26. Rangarajan, M.; Aduse-Opoku, J.; Paramonov, N.; Hashim, A.; Bostanci, N.; Fraser, O.P.; Tarelli, E.; Curtis, M.A. Identification of a second lipopolysaccharide in *Porphyromonas gingivalis* W50. *J. Bacteriol.* **2008**, *190*, 2920–2932. [[CrossRef](#)] [[PubMed](#)]
27. Shah, C.B.; Mittelman, M.W.; Costerton, J.W.; Parenteau, S.; Pelak, M.; Arsenault, R.; Mermel, L.A. Antimicrobial activity of a novel catheter lock solution. *Antimicrob. Agents. Chemother.* **2002**, *46*, 1674–1679. [[CrossRef](#)] [[PubMed](#)]
28. Caruso, F.; Darnowski, J.W.; Opazo, C.; Goldberg, A.; Kishore, N.; Agoston, E.S.; Rossi, M. Taurolidine antiadhesive properties on interaction with *E. coli*; its transformation in biological environment and interaction with bacteria cell wall. *PLoS ONE* **2010**, *5*, e8927. [[CrossRef](#)] [[PubMed](#)]
29. Van Oosten, B.; Marquardt, D.; Komljenovic, I.; Bradshaw, J.P.; Sternin, E.; Harroun, T.A. Small molecule interaction with lipid bilayers: A molecular dynamics study of chlorhexidine. *J. Mol. Graph. Model.* **2014**, *48*, 96–104. [[CrossRef](#)]
30. Gidley, M.J.; Sanders, J.K.; Myers, E.R.; Allwood, M.C. The mode of antibacterial action of some ‘masked’ formaldehyde compounds. *FEBS Lett.* **1981**, *127*, 225–227. [[CrossRef](#)]

31. Bedrosian, I.; Sofia, R.D.; Wolff, S.M.; Dinarello, C.A. Taurolidine, an analogue of the amino acid taurine, suppresses interleukin 1 and tumor necrosis factor synthesis in human peripheral blood mononuclear cells. *Cytokine* **1991**, *3*, 568–575. [[CrossRef](#)]
32. Tang, G.; Kawai, T.; Komatsuzawa, H.; Mintz, K.P. Lipopolysaccharides mediate leukotoxin secretion in *Aggregatibacter actinomycetemcomitans*. *Mol. Oral Microbiol.* **2012**, *27*, 70–82. [[CrossRef](#)] [[PubMed](#)]
33. Ziegler-Heitbrock, H.W.; Thiel, E.; Futterer, A.; Herzog, V.; Wirtz, A.; Riethmuller, G. Establishment of a human cell line (Mono Mac 6) with characteristics of mature monocytes. *Int. J. Cancer* **1988**, *41*, 456–461. [[CrossRef](#)] [[PubMed](#)]
34. Saiki, K.; Konishi, K. Identification of a novel *Porphyromonas gingivalis* outer membrane protein, PG534, required for the production of active gingipains. *FEMS Microbiol. Lett.* **2010**, *310*, 168–174. [[CrossRef](#)]
35. Nguyen, K.A.; Travis, J.; Potempa, J. Does the importance of the C-terminal residues in the maturation of RgpB from *Porphyromonas gingivalis* reveal a novel mechanism for protein export in a subgroup of Gram-Negative bacteria? *J. Bacteriol.* **2007**, *189*, 833–843. [[CrossRef](#)]
36. Baffone, W.; Pianetti, A.; Citterio, B.; Lombardelli, G.; Vittoria, E.; Bruscolini, F. Studies on the development and stability of resistance of *Helicobacter pylori* to metronidazole and clarithromycin. *J. Chemother.* **2001**, *13*, 126–132. [[CrossRef](#)]
37. Eick, S.; Schmitt, A.; Sachse, S.; Schmidt, K.H.; Pfister, W. In vitro antibacterial activity of fluoroquinolones against *Porphyromonas gingivalis* strains. *J. Antimicrob. Chemother.* **2004**, *54*, 553–556. [[CrossRef](#)]
38. Rahman, T.; Yarnall, B.; Doyle, D.A. Efflux drug transporters at the forefront of antimicrobial resistance. *Eur. Biophys. J.* **2017**, *46*, 647–653. [[CrossRef](#)]
39. Poole, K. Efflux-mediated antimicrobial resistance. *J. Antimicrob. Chemother.* **2005**, *56*, 20–51. [[CrossRef](#)]
40. Saleem, H.G.; Seers, C.A.; Sabri, A.N.; Reynolds, E.C. Dental plaque bacteria with reduced susceptibility to chlorhexidine are multidrug resistant. *BMC Microbiol.* **2016**, *16*, 214. [[CrossRef](#)]
41. Mombeshora, M.; Mukanganyama, S. Development of an accumulation assay and evaluation of the effects of efflux pump inhibitors on the retention of chlorhexidine digluconate in *Pseudomonas aeruginosa* and *Staphylococcus aureus*. *BMC Res. Notes* **2017**, *10*, 328. [[CrossRef](#)] [[PubMed](#)]
42. Duraes, F.; Pinto, M.M.M.; de Sousa, M. Medicinal Chemistry Updates on Bacterial Efflux Pump Modulators. *Curr. Med. Chem.* **2018**. [[CrossRef](#)] [[PubMed](#)]
43. Schumacher, A.; Steinke, P.; Bohnert, J.A.; Akova, M.; Jonas, D.; Kern, W.V. Effect of 1-(1-naphthylmethyl)-piperazine, a novel putative efflux pump inhibitor, on antimicrobial drug susceptibility in clinical isolates of Enterobacteriaceae other than *Escherichia coli*. *J. Antimicrob. Chemother.* **2006**, *57*, 344–348. [[CrossRef](#)] [[PubMed](#)]
44. Pumbwe, L.; Glass, D.; Wexler, H.M. Efflux pump overexpression in multiple-antibiotic-resistant mutants of *Bacteroides fragilis*. *Antimicrob. Agents. Chemother.* **2006**, *50*, 3150–3153. [[CrossRef](#)]
45. Nguyen, F.; Starosta, A.L.; Arenz, S.; Sohmen, D.; Donhofer, A.; Wilson, D.N. Tetracycline antibiotics and resistance mechanisms. *Biol. Chem.* **2014**, *395*, 559–575. [[CrossRef](#)]
46. Rams, T.E.; Feik, D.; Mortensen, J.E.; Degener, J.E.; van Winkelhoff, A.J. Antibiotic susceptibility of periodontal *Streptococcus constellatus* and *Streptococcus intermedius* clinical isolates. *J. Periodontol.* **2014**, *85*, 1792–1798. [[CrossRef](#)]
47. Rams, T.E.; Degener, J.E.; van Winkelhoff, A.J. Antibiotic resistance in human chronic periodontitis microbiota. *J. Periodontol.* **2014**, *85*, 160–169. [[CrossRef](#)]
48. Akrivopoulou, C.; Green, I.M.; Donos, N.; Nair, S.P.; Ready, D. *Aggregatibacter actinomycetemcomitans* serotype prevalence and antibiotic resistance in a UK population with periodontitis. *J. Glob. Antimicrob. Resist.* **2017**, *10*, 54–58. [[CrossRef](#)]
49. Veloo, A.C.; Seme, K.; Raangs, E.; Rurenga, P.; Singadji, Z.; Wekema-Mulder, G.; van Winkelhoff, A.J. Antibiotic susceptibility profiles of oral pathogens. *Int. J. Antimicrob. Agents.* **2012**, *40*, 450–454. [[CrossRef](#)]
50. Larsen, T.; Fiehn, N.E. Development of resistance to metronidazole and minocycline in vitro. *J. Clin. Periodontol.* **1997**, *24*, 254–259. [[CrossRef](#)]
51. Eick, S.; Straube, A.; Guentsch, A.; Pfister, W.; Jentsch, H. Comparison of real-time polymerase chain reaction and DNA-strip technology in microbiological evaluation of periodontitis treatment. *Diagn. Microbiol. Infect. Dis.* **2011**, *69*, 12–20. [[CrossRef](#)] [[PubMed](#)]
52. Kachlany, S.C.; Fine, D.H.; Figurski, D.H. Purification of secreted leukotoxin (LtxA) from *Actinobacillus actinomycetemcomitans*. *Protein. Expr. Purif.* **2002**, *25*, 465–471. [[CrossRef](#)]

53. Mosmann, T. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. *J. Immunol. Methods* **1983**, *65*, 55–63. [[CrossRef](#)]
54. Eick, S.; Goltz, S.; Nietzsche, S.; Jentsch, H.; Pfister, W. Efficacy of chlorhexidine digluconate-containing formulations and other mouthrinses against periodontopathogenic microorganisms. *Quintessence Int.* **2011**, *42*, 687–700. [[PubMed](#)]



© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<http://creativecommons.org/licenses/by/4.0/>).